Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Fate Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07216105CT.gov FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07059338CT.gov Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06589830CT.gov TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06245356CT.gov Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | — | Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT06328738CT.gov ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT05356897CT.gov Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | — | Withdrawn | — | — | — |
NCT05725200CT.gov Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
Show 11 more trialsShow fewer
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05091528CT.gov A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | — | Terminated | — | — | — |
NCT04464967CT.gov Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | — | Withdrawn | — | — | — |
NCT04380012CT.gov A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03457896CT.gov Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | — | Unknown | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03185988CT.gov Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | — | Unknown | — | — | — |
NCT02291289CT.gov A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT01960023CT.gov Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT03225937CT.gov Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Fate Therapeutics | P2 | B · 56 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-colorectal-cancer-38831
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →